All research presented here is preliminary. It is not predictive of any effect of NOVOS products on human health.
We are thrilled to share findings that underscore the potential of NOVOS Core in supporting healthy aging. This recent study highlights NOVOS Core’s ability to extend lifespan by an impressive 18% in aged mice, equivalent to starting treatment at 60 human years. The results position NOVOS as a leader in consumer aging intervention research. It is among the largest percentage lifespan improvements in a mouse study, as confirmed by referencing the DrugAge database, which strives to compile all animal lifespan studies and their results.
About the Study
The study was conducted at Newcastle University’s Biosciences Institute by a team of esteemed researchers, including Dr. Thomas von Zglinicki, Professor of Cellular Gerontology with over 43,000 citations, and Dr. Satomi Miwa, Lecturer on the Translational Biology of Aging with over 10,000 citations. This research compared NOVOS Core against both a senolytic drug combination (a “positive control” of interventions previously shown to extend mouse lifespan) and a negative control group with no intervention.
In total, 38 male mice, aged 20 months at the beginning of the study, were divided into three groups: a negative control group, a group receiving NOVOS Core, and a senolytic group. While NOVOS Core was administered daily, the senolytic treatment involved two rounds of injections. Every two months, researchers assessed health markers such as frailty and cognitive function, adding valuable insights into NOVOS Core’s impact on overall healthspan in mice.
Key Findings from the Study
This study on NOVOS Core, our patent-pending longevity formula, uncovered several notable results. The findings added significant depth to the scientific understanding of its impact on aging and healthspan. Here’s a breakdown of the key findings that illustrate why this research is groundbreaking.
1. 18% Lifespan Extension in Aged Mice
NOVOS Core extended lifespan by over 18% in 20-month-old aged mice, equivalent to starting treatment in human 60-year-olds. This impressive relative increase is among the largest percentage lifespan increases of supplements that have been studied in aged mice, highlighting NOVOS Core’s effectiveness in promoting longevity even when interventions begin later in life (p-value = 0.045, +127 days of life). The lifespan benefits exceeded those found in separate lifespan studies of other well-known interventions, such as NR (nicotinamide riboside).
Specifically, as it pertains to NR, in this study of mice aged 22 to 24 months, there was a +5% lifespan extension vs. controls (p-value = 0.034, +39 days of life). In other studies, like this one done as part of the prestigious Interventions Testing Program (ITP) by the National Institute on Aging, there was no lifespan extension at all from NR in either sex of mice, with treatments starting from 8 months.
2. A Powerful, Accessible Approach
The study underscores that NOVOS Core’s natural, multi-ingredient formula can produce better lifespan extension results in mice than R&D longevity treatments, such as:
- TERT gene therapy (13% extension in aged mice)
- Senolytic drugs like the combination of dastatanib and quercetin
- Hormone therapies like 17-alpha-estradiol (12-19% in male mice starting in mid-life, and no improvements in female mice)
These findings suggest that effective longevity interventions can be beneficial to mice even when started later in life.
3. Comparable to R&D Senolytics but with Enhanced Safety
In the study, NOVOS Core matched the lifespan extension benefits of the positive control: prescription-grade R&D senolytic injections of navitoclax combined with BAM15. Unlike many of these treatments, which can be invasive or carry potential side effects, NOVOS Core follows a gentler approach. It leverages natural ingredients that are generally well tolerated by the animals. In an in vitro study conducted by the same team of researchers, senostatic effects were found—reducing the size and slowing the formation of senescent cells rather than eliminating them outright. Research shows that not all senescent cells are harmful, and selectively preserving certain senescent cells may benefit health.
4. Targeting All 12 Mechanisms of Aging
NOVOS Core’s unique formulation was inspired by all 12 scientifically recognized Mechanisms of Aging, a comprehensive scientific framework of aging. This multi-target strategy enables NOVOS Core to deliver health benefits across various aging pathways.
5. Frailty and Cognitive Decline
In addition to extending lifespan, the study found NOVOS Core provided consistent, long-term improvements in health markers for the mice, including reductions in frailty and preservation of cognitive function, but the results did not achieve statistical significance. The study authors suggested that based on the trend towards statistical significance, starting the intervention earlier may have yielded stronger results.
Read the preprint of the study here.
